Thioredoxin in cancer - Role of histone deacetylase inhibitors

被引：60
作者：
Marks, Paul A. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
SEMINARS IN CANCER BIOLOGY | 2006年 / 16卷 / 06期
关键词：
thioredoxin; thioredoxin-binding proteins; histone deacetylase; histone deacetylase inhibitors; suberoylanilide hydroxamic acid;
D O I：
10.1016/j.semcancer.2006.09.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Increased levels of thioredoxin (Trx) occur in a number of human cancers, which may contribute to the resistance of cancers to therapy by scavenging reactive oxygen species (ROS) which are generated by various anti-cancer agents. Many human cancers have low levels of thioredoxin-binding protein (TBP-2). TBP-2 binds to Trx and blocks its reducing activity. Histone deacetylase inhibitors (HDACi) up-regulate TBP-2 in various transformed cells, associated with a decrease in Trx levels. Up-regulation of TBP-2 and decrease of Trx may contribute to the sensitivity of many hematologic and solid tumors to anti-cancer activity of HDACi. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码：436 / 443
页数：8
相关论文
共 94 条
[1]   REDOX REGULATION OF FOS AND JUN DNA-BINDING ACTIVITY INVITRO [J].
ABATE, C ;
PATEL, L ;
RAUSCHER, FJ ;
CURRAN, T .
SCIENCE, 1990, 249 (4973) :1157-1161
[2]   Asymmetric inheritance of oxidatively damaged proteins during cytokinesis [J].
Aguilaniu, H ;
Gustafsson, L ;
Rigoulet, M ;
Nyström, T .
SCIENCE, 2003, 299 (5613) :1751-1753
[3]   Physiological functions of thioredoxin and thioredoxin reductase [J].
Arnér, ESJ ;
Holmgren, A .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 2000, 267 (20) :6102-6109
[4]   Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824 [J].
Atadja, P ;
Gao, L ;
Kwon, P ;
Trogani, N ;
Walker, H ;
Hsu, M ;
Yeleswarapu, L ;
Chandramouli, N ;
Perez, L ;
Versace, R ;
Wu, A ;
Sambucetti, L ;
Lassota, P ;
Cohen, D ;
Bair, K ;
Wood, A ;
Remiszewski, S .
CANCER RESEARCH, 2004, 64 (02) :689-695
[5]  
BANNISTER AJ, 1991, ONCOGENE, V6, P1243
[6]   Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies [J].
Bhalla, KN .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (17) :3971-3993
[7]  
Bjornstedt M, 1997, BIOMED ENVIRON SCI, V10, P271
[8]   The Sir2 family of protein deacetylases [J].
Blander, G ;
Guarente, L .
ANNUAL REVIEW OF BIOCHEMISTRY, 2004, 73 :417-435
[9]  
Blum W, 1996, Z METALLKD, V87, P14
[10]   Biochemical pathways of caspase activation during apoptosis [J].
Budihardjo, I ;
Oliver, H ;
Lutter, M ;
Luo, X ;
Wang, XD .
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, 1999, 15 :269-290
12345678910